Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small...

Area of Science:

• Oncology
• Genetics
• Clinical Research

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard for EGFR-mutant non-small cell lung cancer (NSCLC).
• Treatment outcomes for EGFR-TKI therapy in NSCLC patients vary significantly.
• Concurrent mutations can impact EGFR-TKI effectiveness, but genetic testing is often inaccessible in routine practice.

Purpose of the Study:

• To develop a practical prediction model using pre-treatment clinical characteristics for stratifying NSCLC patients.
• To establish a nomogram to guide optimal first-line treatment strategies for patients with EGFR-mutant NSCLC.
• To identify key prognostic factors influencing progression-free survival in EGFR-mutant NSCLC.

Main Methods:

• Retrospective review of 761 patients with EGFR-mutant NSCLC treated with first- or second-generation EGFR-TKIs.
• Collection of pre-treatment clinical characteristics and progression-free survival data.
• Construction of a nomogram using COX proportional hazard regression analysis based on seven prognostic factors (sex, ECOG performance status, histology, mutation subtype, stage, liver/brain metastasis).

Main Results:

• A nomogram was developed incorporating seven significant prognostic factors.
• The nomogram successfully stratified patients into three distinct risk groups for disease progression.
• Validation in an external patient cohort confirmed the nomogram's predictive capability.

Conclusions:

• The developed nomogram provides a practical tool for risk stratification in EGFR-mutant NSCLC.
• This risk stratification offers valuable information for optimizing first-line treatment decisions.
• The nomogram enhances personalized medicine approaches for NSCLC patients with EGFR mutations.